Eye with DNA strands symbolizing genetic link to thyroid eye disease

Decoding Thyroid Eye Disease: Is a Genetic Link the Key to Better Treatments?

Beau Callahan monogram
Beau Callahan in Health & Wellness October 2026 • 4 min read.

"New research uncovers a potential genetic variant that could increase susceptibility to thyroid eye disease, offering hope for targeted therapies."


Thyroid eye disease (TED), also known as thyroid-associated orbitopathy (TAO), is an autoimmune condition that causes inflammation and damage to the tissues around the eyes. This can lead to a range of symptoms, from mild discomfort and dryness to severe vision impairment and disfigurement. Understanding the factors that contribute to TED is crucial for developing effective treatments and improving the quality of life for those affected.

While Graves' disease, an autoimmune disorder affecting the thyroid gland, is a well-known risk factor for TED, the exact reasons why some individuals with Graves' develop TED while others do not remain unclear. Genetic predisposition is believed to play a significant role, making it essential to identify specific genes that may increase susceptibility to this condition. This knowledge can not only help in predicting who is at higher risk but also in developing targeted therapies that address the root causes of the disease.

Recent research has focused on identifying genetic variants associated with TED in individuals with Graves' disease. This work utilizes advanced techniques like genome-wide association studies (GWAS) to scan the entire genome for genetic markers that are more common in people with TED than in those without it. By identifying these genetic links, researchers aim to unravel the complex mechanisms underlying TED and open new avenues for treatment and prevention.

AI Search Multiple angles on this topic

The Broader Impact of TED

Thyroid eye disease (TED) can significantly affect visual function, appearance, and well-being. A 2025 study used genetic data from the FinnGen R11 database and examined 587 imaging-derived phenotypes to investigate reported links between TED and structural or functional brain changes, although causality remains uncertain. TED also imposes healthcare and economic burdens, while current treatments, including glucocorticoids, teprotumumab, immunosuppressive drugs, and surgery, may have limited effectiveness and high relapse rates. Family history of Graves’ disease, Hashimoto’s thyroiditis, or other autoimmune conditions may increase baseline risk, but not everyone with Graves’ disease develops eye involvement.

Unlocking the Genetic Code: How Does This Study Identify Susceptibility to Thyroid Eye Disease?

Eye with DNA strands symbolizing genetic link to thyroid eye disease

A recent genome-wide association study (GWAS) conducted on Australian Caucasian participants has identified a potential genetic link to thyroid eye disease (TED). The study, which pooled DNA samples from 265 participants with Graves' disease and TED (cases) and 147 patients with Graves' disease without TED (controls), aimed to uncover genetic variants associated with increased susceptibility to TED.

The initial GWAS of pooled DNA samples revealed several single nucleotide polymorphisms (SNPs) showing suggestive associations with TED. SNPs are variations in a single nucleotide that occur at a specific position in the genome and can be used as genetic markers. However, the only SNP that consistently showed association with TED on individual genotyping in both the discovery and replication cohorts was rs6110809.

  • rs953128 located on chr10q21.1
  • rs2867161 on chr7q11.22
  • rs13360861 on chr5q12.3
  • rs7636326 on chr3q26.2
  • rs10266576 on chr 7q11.22
  • rs60457622 on chr3q23
  • rs6110809 on chr20p12.1
AI Search Multiple angles on this topic

A Complex Genetic Landscape

Research on Graves’ orbitopathy has not identified gene variants that confer a specific risk for the condition. Reviews instead describe the genetic basis of Graves’ disease as complex, probably involving several susceptibility genes. None of the reported variants appears sufficient on its own for the disease to occur. This supports a model in which genetic susceptibility may contribute without providing a single definitive genetic explanation.

Why Genetic Findings Remain Unsettled

Evidence for genetic associations in Graves’ disease and Graves’ ophthalmopathy remains limited. A meta-analysis of the TSHR gene states that studies involving different populations and larger sample sizes are needed to confirm the reported associations. Another review notes that a small GWAS had limited analytical power, creating a high risk of both false-positive and false-negative results, while a large, well-powered GWAS on Graves’ ophthalmopathy is still lacking. The use of pooled DNA in another study also limited correction for confounders and assessment of population substructure, potentially producing false-positive findings.

From Risk to Personalized Care

Genetic factors have been described as influencing thyroid eye disease risk and biomarkers. They may also support more personalized approaches to diagnosis and treatment. This framing presents genetics as a potential tool for stratifying patients rather than as a confirmed single-gene explanation for TED. The source does not identify a specific gene or validated genetic test.

The SNP rs6110809 is located within the MACROD2 gene on chromosome 20p12.1. Further analysis of discovery and replication cohorts showed that the minor A allele of rs6110809 was more frequent in individuals with TED than in Graves' disease controls without TED. After adjusting for factors like age, sex, duration of Graves' disease, and smoking, the association remained significant, suggesting that this genetic variant may increase susceptibility to TED in patients with Graves' disease.

What's Next? Confirming the Link and Exploring New Treatments

The discovery of the MACROD2 genetic variant as a potential susceptibility factor for thyroid eye disease opens up new avenues for research and treatment. While these findings are promising, further studies are needed to confirm the association in additional independent cohorts and to fully understand the functional role of MACROD2 in the development of TED. Future research may also focus on exploring the potential of MACROD2 as a therapeutic target, leading to the development of new and more effective treatments for this debilitating condition.

AI Search Multiple angles on this topic

A Complex Autoimmune Disorder

Thyroid-associated ophthalmopathy, also called Graves’ orbitopathy or thyroid eye disease, is described as a complex autoimmune disorder. It can cause orbital disfigurement, double vision, and visual loss. Management includes both surgical and non-surgical approaches. Related coverage presents emerging genetic research as a potential way to better understand thyroid-associated orbitopathy and improve treatment, but it does not establish genetics as a complete explanation.

Toward More Individualized Treatment

Reviews describe a changing treatment landscape shaped by improved understanding of TED mechanisms, emerging therapies, and clinical trials. Future applications may include training artificial-intelligence systems on synthetic data alongside real patient images and data. A major challenge will be identifying the most effective target for each patient rather than relying on a single agent as a universal solution. Long-term safety profiles will also require clarification because unintended downstream immunological effects may emerge.

How the reported associations compare with broader genetic evidence

Broader reviews place these findings within a multifactorial model: no gene variant has been shown to confer a specific risk for Graves ophthalmopathy, and susceptibility may involve several genes rather than a variant sufficient by itself for the disease to occur.[1]

What would clarify the MACROD2 signal

  • The source reports a high risk of false-positive and false-negative results because the genome-wide association analysis had a very small sample size and limited analytical power. A larger, well-powered analysis would be needed to test whether the signal persists.[2]
  • The adjusted MACROD2 estimate may also be affected by incomplete smoking data in the replication and combined datasets. This makes the size and significance of the adjusted association less certain.[3]

Sources

  1. Role of genetics and epigenetics in Graves’ orbitopathy - ScienceDirect (sciencedirect.com, 2024)
  2. 8 Genotype-phenotype correlations in Graves’ disease (www.sciencedirect.com)
  3. Association of Polymorphisms in MACRO Domain Containing ... (iovs.arvojournals.org)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly is thyroid eye disease, and why is it important to understand it?

Thyroid eye disease, also known as thyroid-associated orbitopathy, is an autoimmune condition where the tissues around the eyes become inflamed and damaged. It's significant because it can cause a range of problems, from mild discomfort to severe vision impairment. The implications of TED can greatly affect a person's quality of life, making it crucial to understand and treat the condition effectively. While the connection between Graves' disease and TED is known, further research aims to clarify why some individuals with Graves' develop TED and others do not.

2

What are genome-wide association studies (GWAS), and how are they used in the context of thyroid eye disease?

Genome-wide association studies (GWAS) are used to scan the entire genome to find genetic markers that are more common in people with thyroid eye disease (TED) than in those without it. GWAS are important because they help identify specific genes that may increase a person's susceptibility to TED. By pinpointing these genetic links, researchers can better understand the underlying mechanisms of TED, potentially leading to new treatments and prevention strategies. Techniques like individual genotyping is conducted to validate single nucleotide polymorphisms (SNPs).

3

What are SNPs, and how do they relate to genetic susceptibility of thyroid eye disease?

SNPs, or single nucleotide polymorphisms, are variations in a single nucleotide at a specific position in the genome. They're important genetic markers that can be used to study the genetic basis of diseases like thyroid eye disease (TED). SNPs can help identify genetic variants associated with increased susceptibility to TED, allowing for a better understanding of the disease's underlying mechanisms. One such SNP is rs6110809, located within the MACROD2 gene.

4

What is rs6110809, and why is it significant in thyroid eye disease research?

rs6110809 is a single nucleotide polymorphism (SNP) located within the MACROD2 gene on chromosome 20p12.1. It's significant because research suggests that the minor A allele of rs6110809 is more frequent in individuals with thyroid eye disease (TED) than in those with Graves' disease but without TED. This suggests that this genetic variant may increase susceptibility to TED in patients with Graves' disease, making it a potential target for further research and treatment development.

5

Why is identifying the MACROD2 genetic variant important, and what are the implications for future research and treatment of thyroid eye disease?

The discovery of the MACROD2 genetic variant as a potential susceptibility factor for thyroid eye disease (TED) opens up new avenues for research and treatment. It's important because it provides a specific target for further investigation into the underlying mechanisms of TED. The implication of this discovery is that future research may focus on exploring the potential of MACROD2 as a therapeutic target, leading to the development of new and more effective treatments for TED. However, the functional role of MACROD2 in the development of TED still needs further investigation.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.